skip to content
Detailed Quote
5i Report

Review of Cipher Pharmaceuticals

AUG 16, 2018 - Dermatology pharmaceutical business with recent acquisition and growth in product pipeline, with some mixed results in the past. Coverage dropped until some visibility emerges.

Download Report
Company Profile
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
Q: Results yesterday from CPH and DR both looked excellent and the stock prices have moved up significantly in response. They both look cheap, particularly CPH, even more so if you ex out the $2.20 cash on the balance sheet. What do you think of these as part of a small cap portfolio?
Read Answer Asked by Dan on March 19, 2024
Insiders
Share Information
News and Media